Materials and Methods
cancer, autoimmune disease, Cancer
DISEASE PROGRESSION, CHRONIC INFECTION, BRAIN METASTASES, CANCER, SOLID TUMORS, METASTATIC DISEASE, ONCOLOGY, AUTOIMMUNE DISEASE, CANCER
Patients were recruited at the Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center (SKCCC). Eligible adult patients (≥18 years) had advanced solid tumors and had received at least one standard systemic therapy with chemotherapy, immunotherapy, hormonal therapy, or other therapies for metastatic disease and had disease progression according to the RECIST guideline, version 1.1. Patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 and had a life expectancy longer than 3 months. Major exclusion criteria included (i) history or evidence of brain metastases, (ii) chemotherapy, radiation, hormonal therapy, or biological cancer therapy within 28 days before study treatment initiation, (iii) prior mistletoe treatment, (iv) anticipated other forms of concurrent systemic or localized antineoplastic therapy, and (v) a history of chronic autoimmune disease or chronic infection.